Free press releases distribution network?

Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd - OTAVA Ltd. offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b - OtavaChemicals.com
DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd

 

PRZOOM - /newswire/ - Toronto, Ontario, Canada, 2014/03/11 - OTAVA Ltd. offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b - OtavaChemicals.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

DNA methylation is a major epigenetic modification which plays an important role in controlling gene expression, differentiation and embryonic development. This covalent modification of DNA in mammals is catalyzed by a family of enzymes called methyltransferases.

Methylation abnormalities were identified in both low and high-grade malignancies, supporting the idea that methylation changes can be an early event in tumor progression. Certain tumor types, like colon, glioma, and acute myeloid leukemia, display significantly higher frequency of aberrant methylation events. Therefore, methyltransferases, including DNMT1, 3a and 3b are involved in the progression of many malignant tumors and small compounds inhibiting these enzymes can be used for cancer treatment.

OTAVA Ltd (otavachemicals.com) offers two DNA methyltransferase receptor-based focused compound libraries targeted towards DNMT1 and DNMT3b. Both libraries comprise drug-like compounds only. DNMT1 focused library comprises 503 compounds and DNMT3b targeted library 1320 compounds. The libraries were designed with virtual screening of Drug-like Green Collection. The results of virtual screening were validated with a reference set of known DNMT inhibitors obtained from ChemblDB. Final selection of compounds has been made with inspection of intermolecular hydrogen bonds of ligands with crucial active site’s residues taken from literature reviews, docking score cut-off filtering and exclusion of predicted DNMT1 and DNMT3b cross-binders. Also, 3D pharmacophore model consisting of two hydrogen bond donors, two hydrogen bond acceptors and a hydrophobic region has been applied during the selection.

These libraries provide an excellent basis for development of novel cancer therapeutics.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


DNA Methyltransferases DNMT1 and DNMT3b Target Focused Libraries from Otava Ltd

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Andrey Dmytrenko - OtavaChemicals.com 
416-549-8030 eurasia[.]otavachemicals.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
Sugar Element of Keratan Sulfate Halts the Progress of Emphysema Finds RIKEN
Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada
FDA Extends Review of Application for OCREVUS™ (Ocrelizumab)
MDxHealth Announces AceCGT Life Science Limited as the Exclusive Distributor for SelectMDx in Hong Kong and Macao China
Pulse Certified As A Level Four Multichannel Content Agency by Veeva Systems
BD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Al Rowaad Advocates & Legal Consultants

Visit  NAKIVO, Inc.

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today